Glasdegib CAS# 1095173-27-5 格拉德吉
Glasdegib, also known as PF-04449913, is an orally bioavailable small-molecule inhibitor of the Hedgehog (Hh) signaling pathway with potential antineoplastic activity. Hedgehog inhibitor PF-04449913 appears to inhibit Hh pathway signaling. The Hh signaling pathway plays an important role in cellular growth, differentiation and repair. Constitutive activation of Hh pathway signaling has been observed in various types of malignancies. Glasdegib (PF-04449913) is an FDA approved cancer drug developed by Pfizer. It is a small molecule inhibitor of sonic hedgehog, which is a protein overexpressed in many types of cancer. It inhibits the sonic hedgehog receptor smoothened (SMO), as do most drugs in its class.
📌 参考资料/链接:
Peng, Zhihui; Wong, John W.; Hansen, Eric C.; Puchlopek-Dermenci, Angela L. A.; Clarke, Hugh J. Development of a Concise, Asymmetric Synthesis of a Smoothened Receptor (SMO) Inhibitor: Enzymatic Transamination of a 4-Piperidinone with Dynamic Kinetic Resolution. Hugh J. Organic Letters. Volume 16. Issue 3. Pages 860-863. Journal; Online Computer File. (2014).
📄 详细内容
CAS No. 1095173-27-5 格拉德吉Glasdegib synthetic routes

Peng, Zhihui; Wong, John W.; Hansen, Eric C.; Puchlopek-Dermenci, Angela L. A.; Clarke, Hugh J. Development of a Concise, Asymmetric Synthesis of a Smoothened Receptor (SMO) Inhibitor: Enzymatic Transamination of a 4-Piperidinone with Dynamic Kinetic Resolution. Hugh J. Organic Letters. Volume 16. Issue 3. Pages 860-863. Journal; Online Computer File. (2014).
产品链接: CAS No. 1095173-27-5 ››